FIBER OPTIC SENSOR FOR MEASURING LEAD IN BLOOD

在第一阶段，创新伙伴展示了 开发用于测量感兴趣水平的铅的光纤传感器 血液筛查诊所铅离子选择性光纤光极（LISFO） 在2-200之间的响应曲线的线性部分操作 microg/dL（新的CDC关注水平）。使用光纤技术 将提供坚固、紧凑的便携式仪器，并允许低成本 进行血铅浓度筛查。在第二阶段， 将优化条件以确保纤维间的再现性， 样品制备方法将得到优化和自动化， 原型将通过平行测量构建和验证， LISFO与AAS比较的临床样本。仪器将与 配有一台PC，可调节自动操作、处理和报告 数据，以便经过最低限度培训的操作员可以获得可靠的结果 样品污染的机会很小。用户界面将 允许输入患者信息。 建议的商业应用：由于疾病预防控制中心降低了 关注血液中的铅10微克/分升，仪器， 以前用于铅筛查诊所不再提供准确的 阅读在关注的水平。因此，需要一种新的 受培训有限的人员可使用的仪器， 可以提供大规模、低成本的血铅水平测试。的 拟议的仪器将满足铅筛查诊所的要求 并在市场上获得认可

During Phase I, Innovation associates demonstrated the feasibility of developing a fiber optic sensor for measuring lead at levels of interest to blood screening clinics. The Lead Ion Selective Fiber Optrode (LISFO) operates in the linear portion of the response curve between 2-200 microg/dL (the new CDC level of concern). Use of fiber optic technology will provide a rugged, compact portable instrument and allow low cost screenings of blood lead concentrations to be performed. During Phase II, conditions will be optimized to insure inter-fiber reproducibility, sample preparation methods will be optimized and automated, and a pre- prototype will be constructed and validated by parallel measurements on clinical samples comparing LISFO with AAS. The instrument will interface with a PC which will regulate automatic operations and process and report data so that minimally trained operators can achieve reliable results with little opportunity for sample contamination. A user interface will permit entry of patient information. PROPOSED COMMERCIAL APPLICATION: Since the CDC lowered the level of concern for lead in blood to 10 microg/dL, the instruments which have previously been used in lead screening clinics no longer give accurate reading at the level of concern. Consequently, there is a need for a new instrument which is usable by personnel with limited training and which can provide large scale, low cost testing of blood lead levels. The proposed instrument will meet the requirements of lead screening clinics and will find acceptance in that market.